Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.
Fiche publication
Date publication
mars 2020
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ABELY Michel
Tous les auteurs :
Misgault B, Chatron E, Reynaud Q, Touzet S, Abely M, Melly L, Dominique S, Troussier F, Ronsin-Pradel O, Gerardin M, Mankikian J, Cosson L, Chiron R, Bounyar L, Porzio M, Durieu I, Weiss L, Kessler R, Kessler L
Lien Pubmed
Résumé
To investigate the effects of 1-year lumacaftor-ivacaftor treatment on abnormalities in glucose tolerance (AGT) in Phe508del homozygous cystic fibrosis (CF) patients.
Mots clés
CFTR corrector and potentiator, Cystic fibrosis, Glucose tolerance abnormalities, OGTT
Référence
J. Cyst. Fibros.. 2020 Mar 19;: